Mark Andrew Frye
Chair, Department of Psychiatry and Psychology, Mayo Clinic (Rochester, Minnesota)
Data updated
Research Footprint
Mark Andrew Frye appears in 5 tracked papers (2016–2025), most studied alongside Ketamine and Esketamine, across Major Depressive Disorder (MDD), Depressive Disorders and Bipolar Disorder.
Most-cited paper: A consensus statement on the use of ketamine in the treatment of mood disorders (571 citations).
Frequent co-authors: Jennifer Vande Voort, Sanjay Mathew and Gerard Sanacora.
Background & Research
Mark Andrew Frye, M.D., is a psychiatrist at Mayo Clinic in Rochester, Minnesota, where he serves as Chair of Psychiatry and Psychology and as the inaugural Director of the Mayo Clinic Depression Center. His research focuses on mood disorders, bipolar disorder, biomarker development, and translational psychiatry, including ketamine and other novel treatments for depression.
Key Impact
He is a leading mood-disorders psychiatrist whose work has helped shape the clinical evidence base and consensus guidance for ketamine in depression.
Collaboration Network
8 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Mark Andrew Frye is associated with.